Aptar named Gael Touya as president and CEO, effective Sept. 1, 2026, succeeding Stephan Tanda. Touya has more than 30 years at the company and most recently served as president of Aptar Pharma. Tanda will remain an advisor through year-end 2026 and is expected to retire from the board by the end of 2026. The board plans to appoint Touya as a director on Sept. 1, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603171700BIZWIRE_USPR_____20260317_BW319560) on March 17, 2026, and is solely responsible for the information contained therein.
Comments